NeuroRx announces FDA IND clearance for NRX-101 phase 2b/3 study and publication of promising - PR Newswire (press release)

Submitted by Anonymous (not verified) on Wed, 01/04/2017 - 15:08

NeuroRx announces FDA IND clearance for NRX-101 phase 2b/3 study and publication of promisingPR Newswire (press release)The current standard of care, as published by the American Psychiatric Association consists of voluntary or forced admission to a psychiatric hospital and electroconvulsive therapy (ECT). Although ECT is associated with a decrease in suicide deaths, ...